Virtual Hospital Logo Virtual Hospital Home Virtual Children's Hospital Home Site Map Mirrors Search Health Topics A-Z for Providers Textbooks for Providers Health Topics A-Z for Patients Textbooks for Patients About Us Continuing Education Translations Links Support Us University of Iowa Health Care
For Patients

Pulmonary Hypertension

Traci Stewart, R.N., B.S.N.
UI Heart Care, Pulmonary Hypertension Program
University of Iowa Hospitals and Clinics

Creation Date: January 2002
Last Revision Date: January 2002
Peer Review Status: Internally Peer Reviewed


Definition of Pulmonary Hypertension
Pulmonary Hypertension (PH) is a rare, progressive condition characterized by elevation in the blood pressure of the arteries of the lung. There are many causes of PH. When no known disease causes PH, it is called primary pulmonary hypertension (PPH). If another illness causes PH, such as, scleroderma, rheumatoid arthritis, portal hypertension, chronic bronchitis/emphysema, sleep apnea, blood clot in the lungs, or lung fibrosis, it is called secondary pulmonary hypertension (SPH).

The normal peak pulmonary artery pressure is approximately 25 mm Hg, while PH patients have pressures above 40 mm Hg. The pulmonary arteries deliver blood from the right side of the heart to the lungs to pick up oxygen; and the right side of the heart becomes enlarged, if it has to pump against high pressures in the pulmonary arteries. As PH progresses, the right heart may have increasing difficulty and ultimately may fail.

Symptoms
Symptoms of pulmonary hypertension include shortness of breath, tiredness, cough, dizziness or fainting spells, chest pain, and swelling in the ankles or abdomen. Since PH is such an unusual disease, often these symptoms have become quite severe before a diagnosis is made.

Diagnosis
Testing must be done to evaluate for secondary causes of pulmonary hypertension. Therefore, an electrocardiogram (EKG), chest x-ray, echocardiogram, ventilation perfusion scan, and pulmonary function tests help to eliminate other causes for pulmonary hypertension. Blood work including thyroid functions and serology for ANA and HIV also can help determine secondary causes. Often pulmonary angiography, computed tomography (CAT scan) or sleep studies may be beneficial in diagnosing the cause. Cardiac catherization is done to diagnose and determine the severity of the pressures in the pulmonary arteries, exclude congenital heart defects, and measure response to medications.

Treatment
Treating PH with medications that dilate the pulmonary arteries can improve symptoms and the strain on the right side of the heart. Medication that make the blood flow easier through the pulmonary arteries called anticoagulants, and that pull off fluid from the body called diuretics are also used. Calcium channel blockers are a medication taken by mouth that in some patients, lower the pressure in the pulmonary arteries. Oxygen can prevent further constriction of the pulmonary arteries when oxygen levels in the blood are low.

A medication called Flolan® imitates a naturally occurring chemical in the body, called prostacyclin, that dilates blood vessels, including the pulmonary arteries. Flolan® is an intravenous medication, which is infused through a permanent catheter in the chest, called a central line. A pump ensures this medication is delivered at a slow and continuous rate, because this medication can not be interrupted. Flolan® can have effects of flushing, nausea, diarrhea, headaches, and jaw pain and can be complicated by central line infections. Since this medication is complex to administer, it needs to be given by health professionals with expertise in this area.

Further research is constantly looking for ways to treat PH without the risks of an intravenous medication. Bosentan® is a pill which blocks a hormone called endothelin. Endothelin is made in the lung and is found in higher levels in PH patients, leading to resistance of blood flow through the lungs and higher pressures in the pulmonary arteries. Bosentan® has recently been approved by the F.D.A., as an approved therapy for PH.

A medication given continually under the skin, (which eliminates the need for a central line) is called Remodulin®. This medication requires less frequent mixing, and does not need to be kept chilled as does Flolan®, but does not have as strong of dilating effects. Remodulin® is being reviewed by the F.D.A., as an approved therapy for PH.

Iloprost® is an inhaled form of prostacyclin, which dilates pulmonary arteries and lowers pulmonary artery pressures. It is still in the study phase and does not have F.D.A. approval.

Beraprost® is a pill form of prostacyclin, which continues to be researched for it’s effects on PH, and is not approved by the F.D.A.

Visit UI Health Care on the web for more information about UI Heart Care's Pulmonary Hypertension Program.


See related Patient Textbooks about Internal Medicine.

See related Patient Topics Heart and Circulation, Heart Diseases--General, Internal Medicine, Lungs and Breathing, Pulmonary, Respiratory Diseases--General or Seniors' Health.

See related Provider Textbooks about Internal Medicine.

See related Provider Topics Heart and Circulation, Heart Diseases--General, Internal Medicine, Lungs and Breathing, Pulmonary, Respiratory Diseases--General or Seniors' Health.


Virtual Hospital Home | Virtual Children's Hospital Home | Site Map | Mirror Sites | Search

Provider Health Topics A-Z | Provider Textbooks | Patient Health Topics A-Z | Patient Textbooks

About Us | Continuing Education | Translations | Links | Support Us

Policies | Comments and Questions | E-mail This Page | UI Health Care Home


All contents copyright © 1992-2004 the Author(s) and The University of Iowa. All rights reserved.

http://www.vh.org/adult/patient/internalmedicine/pulmonaryhypertension/index.html